Back to search

Article

Risk of Adverse Pregnancy Outcomes Associated with Sodium Valproate(VPA): A Disproportionality Analysis Using the FDA Adverse Event Reporting System (FAERS)

2025-05-15

Abstract excerpt

<title>Abstract</title> <p> <bold>Background:</bold> Valproate(VPA) is widely used for treating epilepsy, bipolar disorder, and migraines. However, its use during pregnancy raises concerns due to potential adverse events (AEs) on fetal development. Previous studies have linked VPA to neural tube defects, cardiac malformations, and cognitive impairments in offspring. Despite these risks, some pregnant women cont...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
347048a4-cf45-5fc8-afc7-0721d773da41
DOI
10.21203/rs.3.rs-6482152/v1
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Risk of Adverse Pregnancy Outcomes Associated with Sodium Valproate(VPA): A Disproportionality Analysis Using the FDA Adverse Event Reporting System (FAERS)DOI 10.21203/rs.3.rs-6482152/v1
Select a neighboring publication to make it the new centre.